MBX Biosciences (NYSE:MBX) Stock Price Down 3.5% - Should You Sell?

Shares of MBX Biosciences, Inc. (NYSE:MBX - Get Free Report) traded down 3.5% on Friday . The stock traded as low as $23.26 and last traded at $23.64. 19,697 shares traded hands during trading, a decline of 86% from the average session volume of 142,220 shares. The stock had previously closed at $24.50.

MBX Biosciences Stock Down 3.7 %

Insider Activity at MBX Biosciences

In other news, major shareholder Life Sciences X. L.P. Frazier bought 625,000 shares of the stock in a transaction dated Monday, September 16th. The shares were bought at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the insider now owns 4,552,774 shares in the company, valued at approximately $72,844,384. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Edward T. Mathers purchased 500,000 shares of MBX Biosciences stock in a transaction on Monday, September 16th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the transaction, the director now owns 3,614,486 shares of the company's stock, valued at approximately $57,831,776. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Life Sciences X. L.P. Frazier acquired 625,000 shares of the company's stock in a transaction dated Monday, September 16th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the insider now directly owns 4,552,774 shares in the company, valued at $72,844,384. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.